IRVINE, Calif., Sept. 28, 2021 — Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that management will host a key opinion leader (KOL) webinar on McArdle Disease and other genetic mitochondrial myopathies on Monday, October 4,… Continue reading Reneo Pharmaceuticals Hosting Key Opinion Leader Webinar on McArdle Disease and other Genetic Mitochondrial Myopathies
